CYP2C19 acts on 5-10% of drugs in current clinical use. About 2-6% of individuals of European origin, 15-20% of Japanese, and 10-20% of Africans have a slow acting, poor metabolizer form of this enzyme. However there is wide variability among populations. For example, the percent of Polynesians who are poor metabolizers ranges from 38-79% depending on location. CYP2C19 is an important drug metabolizing enzyme that catalyzes the biotransformation of many other clinically useful drugs including antidepressants, barbiturates, proton pump inhibitors, antimalarial and antitumor drugs.
Genelex offers improved detection rates using an extended Cytochrome P450 2C19 DNA test. This test identifies 8 small nucleotide variants in PCR-multiplex format, providing increased sensitivity and quality performance. This CYP2C19 detection panel is the most extensive on the market and covers seven known poor metabolizer alleles and one known rapid metabolizer allele. Analytical specificity and sensitivity for detection of these mutations are >99%.
Indication for Testing
For individuals with a personal or family history of adverse drug reactions to medications metabolized by CYP2C19. Confirm presence of genotypes that affect the metabolism of drugs such as Plavix that are metabolized by cytochrome CYP2C19.
CYP2C19 genotyping is covered by most private insurers and by Medicare in specific instances. Visit the Center for Medicare & Medicaid Services’ Local Coverage Determination for CYP2C19 by clicking here (you will be prompted to review and the CMS licensing information before being directed to the LCD).
Click here to order testing supplies or call Client Services at 800-837–8362.
- Buccal Swabs: 4 sterile buccal swabs
- Blood: 5-10cc whole blood lavender-top EDTA or yellow-top ACD-A tubes
Turnaround Time: 5 days, 4 day STAT